Efficacy of I-131 MIBG Myocardial Scintigraphy for the Differentiation Between Parkinson’s Disease and Multiple System Atrophy

Mehmood Hussain; Fida  Hussain; Asad  Malik; Malik Nadeem Azam  Khan; Zaigham  Saleem; Maryam  Rehman

doi:10.51253/pafmj.v74i6.8384

Authors

Mehmood Hussain Department of Medicine, Pak Emirates Military Hospital/National University of Medical Sciences (NUMS), Rawalpindi Pakistan
Fida Hussain Department of Medicine, Armed Forces Institute of Pathology/National University of Medical Sciences (NUMS), Rawalpindi Pakistan
Asad Malik Department of Medicine, Armed Forces Institute of Pathology/National University of Medical Sciences (NUMS), Rawalpindi Pakistan
Malik Nadeem Azam Khan Department of Medicine, Combined Military Hospital Kharian/National University of Medical Sciences (NUMS), Pakistan
Zaigham Saleem Department of Medicine, Armed Forces Institute of Pathology/National University of Medical Sciences (NUMS), Rawalpindi Pakistan
Maryam Rehman Department of Medicine, Pak Emirates Military Hospital/National University of Medical Sciences (NUMS), Rawalpindi Pakistan

DOI:

https://doi.org/10.51253/pafmj.v74i6.8384

Keywords:

3-Iodobenzylguanidine, Metaiodobenzylguanidine, Multiple System Atrophy, Parkinson Disease, Sympathetic Nervous System.

Abstract

Objective: To assess efficacy of I-131 Metaiodobenzylguanidine Myocardial Scintigraphy for differentiation between Parkinson’s Disease and Multiple System Atrophy.

Study Design: Validation Study.

Place and Duration of Study: Department of Neurology, Pakistan Emirates Military Hospital, Rawalpindi Pakistan, from May 2019 to Jan 2022.

Methodology: Undiagnosed patients with motor and autonomic symptoms of Parkinsonism were enrolled. I-131 Meta-iodobenzylguanidine Myocardial Scintigraphy was performed and subjects were diagnosed as per early (15 min) and late (4h) heart/mediastinum ratios with washout ratio. At the same time, patients were reviewed for clinical diagnosis using clinical criteria, radiological studies and followed up for 2 years or till definitive clinical diagnosis was formed. Sensitivity and Specifi-city of I-131 Metaiodobenzylguanidine for Diagnosis of Parkinson’s Disease and Multiple System Atrophy was calculated.

Results: Out of 79 patients, 48 were diagnosed with Parkinson’s Disease, 15 with Multiple System Atrophy and 16 fell in criteria for other diseases. Early heart/mediastinum, Late heart/mediastinum and washout ratio in Parkinson’s group was 1.53±0.19, 1.39±0.18 and 37.20±17.91, in Multiple System Atrophy was 2.02±0.10, 2.00±0.11 and 11.35±9.46 and in others was 2.36±0.18, 2.41±0.18 and 0.40±22.49 respectively. This revealed a sensitivity and specificity of 83.67% and 76.67% for Parkinson’s Disease and 66.67% and 92.19% for Multiple System Atrophy respectively.

Conclusion: I-131 Metaiodobenzylguanidine can be used to help in differential diagnosis of Parkinsonism with autonomic features, with good sensitivity and specificity.

Downloads

Download data is not yet available.

References

Visanji N, Lang A, Kovacs G. Beyond the synucleinopathies: alpha synuclein as a driving force in neurodegenerative comorbidities. Transl Neurodegener 2019; 8(1): 1-13.

https://doi.org/10.1186/s40035-019-0172-x

Abos A, Baggio H, Segura B, Campabadal A, Uribe C, Giraldo D, et al. Differentiation of multiple system atrophy from Parkinson’s disease by structural connectivity derived from probabilistic tractography. Sci Rep 2019; 9(1): 16488.

https://doi.org/10.1038/s41598-019-52829-8

Krismer F, Wenning G. Multiple system atrophy: insights into a rare and debilitating movement disorder. Nat Rev Neurol 2017; 13(4): 232-243.

https://doi.org/10.1038/nrneurol.2017.26

Berardelli A, Wenning G, Antonini A, Berg D, Bloem B, Bonifati V, et al. EFNS/MDS-ES recommendations for the diagnosis of Parkinson's disease. Eur J Neurol 2012; 20(1): 16-34.

https://doi.org/10.1111/ene.12022

Lee J, Yun J, Shin C, Kim H, Jeon B. Putaminal abnormality on 3-T magnetic resonance imaging in early parkinsonism-predominant multiple system atrophy. J Neurol 2010; 257(12): 2065-2070.

https://doi.org/10.1007/s00415-010-5661-x

Palma J, Norcliffe-Kaufmann L, Kaufmann H. Diagnosis of multiple system atrophy. Auton Neurosci 2018; 211: 15-25.

https://doi.org/10.1016/j.autneu.2017.10.007

Druschky A, Hilz M, Platsch G, Radespiel-Tröger M, Druschky K, Kuwert T, et al. Differentiation of Parkinson’s disease and multiple system atrophy in early disease stages by means of I-123-MIBG–SPECT. J Neurol Sci 2000; 175(1): 3-12.

https://doi.org/10.1016/S0022-510X(00)00279-3

Chung E, Lee W, Yoon W, Kim B, Lee G. MIBG scintigraphy for differentiating Parkinson's disease with autonomic dysfunction from Parkinsonism-predominant multiple system atrophy. Mov Disord 2009; 24(11): 1650-1655.

https://doi.org/10.1002/mds.22649

Yang T, Wang L, Li Y, Cheng M, Jiao J, Wang Q, et al. I-131 MIBG myocardial scintigraphy for differentiation of Parkinson's disease from multiple system atrophy or essential tremor in Chinese population. J Neurol Sci 2017; 373(1): 48-51.

https://doi.org/10.1016/j.jns.2016.12.006

López A, Wagner D, Wang J. Characterization of Meta-Iodobenzylguanidine (mIBG) Transport by Polyspecific Organic Cation Transporters: Implication for mIBG Therapy. Mol Pharmacol 2020; 98(2): 109-119.

https://doi.org/10.1124/mol.120.119495

Postuma R, Berg D, Stern M, Poewe W, Olanow C, Oertel W, et al. MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord 2015; 30(12): 1591-1601.

https://doi.org/10.1002/mds.26424

Wenning G, Gilman S, Seppi K. Second consensus statement on the diagnosis of multiple system atrophy. Aktuelle Neurol 2008; 35(S01)M394.

https://doi.org/10.1055/s-0028-1086654

Xu D, Zhu W, Huo L, Zhu S, Li F, Wang H. Validation of Iodine-131-meta-iodobenzylguanidine cardiac scintigraphy in Parkinsonism: A preliminary study. Parkinsonism Relat Disord 2018; 50: 69-73. https://doi.org/10.1016/j.parkreldis.2018.02.020

Braune S, Reinhardt M, Schnitzer R, Riedel A, Lucking C. Cardiac uptake of [123I]MIBG separates Parkinson's disease from multiple system atrophy. Neurol 1999; 53(5): 1020-1020.

https://doi.org/10.1212/WNL.53.5.1020

Chen J, Wang Q. On the utility of multiple-phase I-131 MIBG myocardial scintigraghy in cardiac sympathetic function evaluation and differential diagnosis of Parkinson's Disease, Multiple System Atrophy and Essential Tremor in Chinese population. J Nucl Med 2018; 59(1): 1701.

Kawazoe M, Arima H, Maeda T, Tsuji M, Mishima T, Fujioka S, et al. Sensitivity and specificity of cardiac I-123 MIBG scintigraphy for diagnosis of early-phase Parkinson's disease. J Neurol Sci 2019; 407(1): 116409. https://doi.org/10.1016/j.jns.2019.07.027

Ryu D, Kim J, Lee J, Oh Y, Yoo S, Yoo I, et al. Initial Versus Follow-up Sequential Myocardial I-123 MIBG Scintigraphy to Discriminate Parkinson Disease From Atypical Parkinsonian Syndromes. Clin Nucl Med 2019; 44(4): 282-288.

https://doi.org/10.1097/RLU.0000000000002424

Fujita H, Suzuki K, Numao A, Watanabe Y, Uchiyama T, Miyamoto, et al. Usefulness of Cardiac MIBG Scintigraphy, Olfactory Testing and Substantia Nigra Hyperechogenicity as Additional Diagnostic Markers for Distinguishing between Parkinson’s Disease and Atypical Parkinsonian Syndromes. PLoS ONE 2016; 11(11): e0165869.

https://doi.org/10.1371/journal.pone.0165869

King A, Mintz J, Royall D. Meta-analysis ofI-123 MIBG cardiac scintigraphy for the diagnosis of Lewy body-related disorders. Mov Disord 2011; 26(7): 1218-1224.

https://doi.org/10.1002/mds.23659

Treglia G, Stefanelli A, Cason E, Cocciolillo F, Di Giuda D, Giordano A. Diagnostic performance of iodine-123-metaiodobenzylguanidine scintigraphy in differential diagnosis between Parkinson's disease and multiple-system atrophy: A systematic review and a meta-analysis. Clin Neurol Neurosurg 2011; 113(10): 823-829. https://doi.org/10.1002/mds.23659

Orimo S, Takahashi A, Uchihara T, Mori F, Kakita A, Wakabayashi K, et al. Degeneration of Cardiac Sympathetic Nerve Begins in the Early Disease Process of Parkinson’s Disease. Brain Pathol 2007; 17(1): 24-30.

https://doi.org/10.1111/j.1750-3639.2006.00032.x